Analytical Data
-
基因名
PNMA6A
- Application
-
别名
PNMA6A; PNMA6C; Paraneoplastic antigen-like protein 6A
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P0CW24
-
表达区间
1-399 aa
-
氨基酸序列
MAVTMLQDWC RWMGVNARRG LLILGIPEDC DDAEFQESLE AALRPMGHFT VLGKVFREED NATAALVELD REVNYALVPR EIPGTGGPWN VVFVPRCSGE EFLGLGRVFH FPEQEGQMVE SVAGALGVGL RRVCWLRSIG QAVQPWVEAV RYQSLGVFSG RDQPAPGEES FEVWLDHTTE MLHVWQGVSE RERRRRLLEG LRGTALQLVH ALLAENPART AQDCLAALAQ VFGDNESQAT IRVKCLTAQQ QSGERLSAFV LRLEVLLQKA MEKEALARAS ADRVRLRQML TRAHLTEPLD EALRKLRMAG RSPSFLEMLG LVRESEAWEA SLARSVRAQT QEGAGARAGA QAVARASTKV EAVPGGPGRE PEGLRQAGGQ EAEELLQEGL KPVLEECDN
-
分子量
43.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PNMA6A (Paraneoplastic Ma Antigen 6A) is a potential oncoantigen associated with various malignancies, particularly in neuroblastoma and other tumors. Its significance has attracted attention due to its involvement in paraneoplastic neurological syndromes, where it may evoke immune responses in cancer patients. Research indicates that PNMA6A plays a role in neuronal development and survival, making it a focal point for understanding tumor immunology and potential therapeutic applications. The protein's expression is often correlated with tumor progression and patient prognosis, leading to investigations into its utility as a biomarker for cancer detection and treatment response. Moreover, the recombinant production of PNMA6A allows for detailed studies on its structure, function, and interactions with the immune system. This has potential implications for developing vaccine strategies or immunotherapies targeting PNMA6A-expressing tumors. As research continues, understanding the molecular mechanisms underlying PNMA6A's interactions with immune cells could pave the way for innovative approaches in cancer treatment, highlighting the importance of this protein in both clinical and laboratory settings.
